Cargando…
Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia
Autoimmune hemolytic anemia is a rare condition characterized by destruction of red blood cells with and without involvement of complement. It is associated with significant morbidity and mortality. In warm autoimmune hemolytic anemia, less than 50% of patients remain in long-term remission followin...
Autor principal: | Murakhovskaya, Irina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763062/ https://www.ncbi.nlm.nih.gov/pubmed/33322221 http://dx.doi.org/10.3390/jcm9124034 |
Ejemplares similares
-
Development of New Drugs for Autoimmune Hemolytic Anemia
por: Xiao, Zhengrui, et al.
Publicado: (2022) -
Cold autoimmune hemolytic anemia resolved by rituximab
por: Palombi, Massimiliano, et al.
Publicado: (2010) -
P1697: CHARACTERISTICS, TREATMENT PATTERNS AND HEALTHCARE UTILIZATION OF PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA INITIATING FIRST LINE THERAPY OF ORAL CORTICOSTEROIDS WITH OR WITHOUT RITUXIMAB
por: Murakhovskaya, Irina, et al.
Publicado: (2023) -
Warm and Cold Autoimmune Hemolytic Anemia in the Setting of COVID-19 Disease
por: Brazel, Danielle, et al.
Publicado: (2021) -
Immunotherapy Treatments of Warm Autoimmune Hemolytic Anemia
por: Liu, Bainan, et al.
Publicado: (2013)